The national drug alliance procurement office has released a notification initiating the drug information filing process for the 8th volume-based procurement (VBP) round. This round is a significant step in the ongoing efforts to streamline and optimize the procurement of pharmaceuticals in China.
Registration and Information Submission
As of February 20, 2023, relevant manufacturers are required to visit the National Drug Alliance Procurement Platform for company registration and information submission. This platform serves as the central hub for all participating manufacturers to submit their drug information and register their companies for the procurement process.
Scope of the 8th VBP Round
The 8th VBP round will involve 41 drug varieties across 181 specifications, with 27 of these being injectables. The disease areas targeted in this round include infection, cardiovascular diseases, and other treatment areas. Notably, this is the first time that heparin products such as nadroparin and enoxaparin are to be affected by the VBP. This inclusion marks a significant expansion in the types of drugs covered under the procurement program, aiming to improve access to a broader range of essential medications.-Fineline Info & Tech
